Effect of Varenicline on Smoking Cessation Through Smoking Reduction: A Randomized Clinical Trial

Ebbert, Jon O.; Hughes, J. R.; West, R

doi:10.1016/j.jvs.2015.04.415

Cited by 39 publications

(68 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, the effect of telling SLA on smoking quit rate was lost, considering the relapse rate at 1 year after successful quit on Visit 5: 21.4% (6/28) in the SLA group vs. 31.0% (9/29) in controls. Agboola et al demonstrated a 55% relapse after abstinence from smoking at week 52 among varenicline users (20), whereas Ebbert et al showed that abstinence rates from smoking among varenicline users were 32% during 15 through 24 weeks and 27% during 21 through 52 weeks (21). Compared to those reports, the relapse rates seemed to be lower in our study.…”

Section: Discussioncontrasting

confidence: 84%

Effect of telling patients their “spirometric-lung-age” on smoking cessation in Japanese smokers

et al. 2017

View full text Add to dashboard Cite

Background: Cigarette smoking remains a significant public health problem. However, current treatment programs have not yet succeeded in sufficiently reducing smoking rates. The study aimed to examine whether patients' recognition of "spirometric-lung-age (SLA)" estimated from spirometry data prompts smoking cessation. Methods: From December 2010 to September 2011, participating smokers were prospectively enrolled into the standardized smoking cessation program (Visits 1-5 for 12 weeks) and assigned single-blindly to either SLA assessment or control groups. The SLA group was informed of the estimated age of their lungs from spirometry analysis and given an opportunity to recognize the difference from their actual chronological age, whereas the control group was not. The primary calculation of outcome was the smoking quit rate on Visit 5, whereas the secondary end-point was the proportion of patients who remained abstinent 1 year later. Results: One hundred and twenty-six Japanese smokers (88 males) participated and were randomly assigned to the SLA group (n=52) or the control group (n=74). The smoking quit rate on Visit 5 was similar in the SLA assessment group and control group (59.6% vs. 41.9%; P=0.0700). However, the proportion of patients who remained abstinent 1 year later was similar in both groups (78.6% vs. 69.0%; P=0.5497). Multivariate logistic regression analysis after adjusting baseline characteristics demonstrated that telling patients their SLA, the use of varenicline, and age were significantly associated with smoking quit rate on Visit 5 whereas only age was associated with remaining abstinent 1 year later.Conclusions: Telling patients their SLA can become a useful tool prompting smoking cessation among Japanese smokers although other factors such as pharmacotherapy and age also influence the cessation of smoking.

show abstract

Section: Discussioncontrasting

confidence: 84%

Effect of telling patients their “spirometric-lung-age” on smoking cessation in Japanese smokers

et al. 2017

View full text Add to dashboard Cite

show abstract

“…All these aids were shown to be more effective than placebo [18][19][20] . In general, the results of this study follow the trend observed from previous literature with varenicline alongside with behavioural counselling appearing to be the most effective, with a 12-month point-prevalence abstinence rate of 34.3%.…”

Section: Tobacco Prevention and Cessationmentioning

confidence: 99%

A 4-year Follow-up Evaluation Of A Pharmacist-managed Smoking Cessation Programme With Emphasis On Effectiveness Of Different Treatment Modalities

Poh¹,

Ng²

2016

Tob. Prev. Cessation

View full text Add to dashboard Cite

INTRODUCTION Smoking cessation clinic (SCC) was introduced into Singapore's healthcare setting to combat the increase in smoking prevalence. This study aims to determine (1)the effectiveness of a pharmacist-managed SCC, and (2)the association between abstinence rates and different treatment modalities, in Changi General Hospital. METHODS 445 patients who had attended the SCC were retrospectively reviewed. These patients received structured smoking cessation counselling with or without additional cessation aid comprising of nicotine replacement therapy (NRT), varenicline or bupropion. The study end points were point-prevalence abstinence rates (1)for all subjects, and (2)associated with various treatment modalities, at the final SCC review, 6-and 12-month follow-up. RESULTS The point-prevalence abstinence rates for all patients at completion of SCC review, 6-and 12-month follow-up were 19.8%, 23.8% (p=0.033), and 25.4% (p=0.009), respectively. Abstinence rates between 6-and 12-month follow-up were not statistically different. A significant association between abstinence rates and the use of pharmacotherapy was detected at 6-months' follow-up (p=0.005), but not at SCC review completion or 12-months' follow-up (p>0.05). Abstinence rates were highest at 6-and 12-month with use of varenicline (37.4% and 34.3%, respectively) followed by combination NRT (21.7% and 26.1%). Furthermore, patients who had received only smoking cessation counselling had abstinence rates of 20.7% and 26.0% at 6-and 12-month follow-up. CONCLUSIONS Patient participation in a pharmacist-managed SCC was associated with significantly improved abstinence rates at 6-and 12-months following programme completion. The use of pharmacotherapy was significantly associated with overall abstinence rates at 6-months' followup with varenicline appearing as the most effective smoking cessation aid.

show abstract

“…It is known to be a blocker; however, it does have partial receptor activator properties; it penetrates the brain and stimulates dopamine release in the reward center. A study on the effect of varenicline for 6 months and one year on smoking cessation via smoking reduction, when compared to placebo was shown to drastically reduce smoking in participants [8,22,23,30,35]. …”

Section: Traditional Pharmacological Methodsmentioning

confidence: 99%

Untitled

2016

International Journal of Medical and Health Sciences Research

View full text Add to dashboard Cite

show abstract

Effect of Varenicline on Smoking Cessation Through Smoking Reduction: A Randomized Clinical Trial

Cited by 39 publications

References 0 publications

Effect of telling patients their “spirometric-lung-age” on smoking cessation in Japanese smokers

Effect of telling patients their “spirometric-lung-age” on smoking cessation in Japanese smokers

A 4-year Follow-up Evaluation Of A Pharmacist-managed Smoking Cessation Programme With Emphasis On Effectiveness Of Different Treatment Modalities

Untitled

Contact Info

Product

Resources

About